Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.

Inclusion criteria

• Patients, who have undergone hysterectomy for curative intent, with histologically confirmed endometrioid adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma
• Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy), meeting one of the following conditions:

• High grade histology OR
• Outer-half myometrial invasion and FIGO grade 1-2 OR
• FIGO stage II - IIIC1 (all gross nodal disease must be resected)
• Patient is willing and able to give informed consent to participate in this clinical trial.
• Age ≥18 years.
• Patients who are to receive adjuvant systemic therapy in addition to pelvic radiotherapy will be eligible provided that there is at minimum a 3-week interval between any radiation treatment and chemotherapy treatments. Adjuvant systemic therapy may be given before or after radiation treatment.
• Patient must be willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol.
• Primary language of the patient must be English or, if a patient's primary language is not English, they are still able to participate provided the QLQ-C30 and EN-24 is available in their primary language.

Exclusion criteria

• Patient has had prior pelvic radiotherapy.
• Patient has received neo-adjuvant systemic therapy
• Patient has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease.
• Patient has a contraindication to iodinated CT contrast.
• Patient has a hip prosthesis.